Baylor College of Medicine Receives $822,000 in Komen Grants

Jo-Carolyn Goode | 9/22/2015, 3:26 p.m.
Researchers from the NCI-Comprehensive Designated Dan L. Duncan Cancer Center at Baylor College of Medicine have received over $822,000 in ...
Baylor College of Medicine

HOUSTON – (Sep. 22, 2015) -- Researchers from the NCI-Comprehensive Designated Dan L. Duncan Cancer Center at Baylor College of Medicine have received over $822,000 in grant funding from Susan G. Komen for four new projects in breast cancer research.

The new grants were awarded to:

Dr. Jeffrey Rosen, a Komen Scholar and the Charles C. Bell Professor of Molecular and Cellular Biology at Baylor, received a $400,000 grant to test novel targeted therapies for the treatment of triple negative breast cancer. Rosen is a member of the Lester and Sue Smith Breast Center at Baylor and leader of the breast cancer research program of the Duncan Cancer Center.

Dr. Xian Wang, a post-doctoral associate in the lab of Dr. Xiaosong Wang, an assistant professor in the Smith Breast Center at Baylor, received a $180,000 grant to study the potential of a novel targeted therapy, which targets nemo like kinase, to treat endocrine-resistant breast cancers. His work will also identify potential biomarkers to predict response to therapy.

Dr. Yuanzhang Fang, a post-doctoral associate in the lab of Dr. Yi Li, associate professor in the Smith Breast Center, received a $180,000 grant to determine whether drugs that target interleukin-1 can stop the growth of cancer stem cells in triple negative breast cancer. He will also validate a new marker that can be used to more easily isolate cancer stem cells.

Dr. Bert O’Malley, a Komen Scholar and chair and professor of molecular and human genetics at Baylor, received a $62,500 to better understand the roles of TRAF4 and ERK3 in driving breast cancer progression, cell migration and invasion, and therapy resistance. O’Malley also serves as associate director of the Duncan Cancer Center.

For more information, visit bcm.edu